Autosomal Dominant Polycystic Kidney Clinical Trial
Official title:
Treatment of Vascular Stiffness in Patients With Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease characterized by cystic kidneys and caused by mutations in the polycystic kidney disease and other rare genes. It is associated with salt-sensitive hypertension, which accounts for the majority of morbidity and mortality. About 70% of patients with ADPKD develop hypertension, prior to the onset of kidney function decline. Early onset hypertension, despite its treatment, is independently associated with rapid kidney function decline. The investigators hypothesize that a high-sodium diet in patients with ADPKD is required for the development of vascular stiffness, which precedes hypertension, and that treatment with amiloride reverses this phenomenon.
Objective of the study: The investigators aim to investigate if arterial stiffness is exacerbated due to a high-salt diet in patients with ADPKD. The investigators also aim to explore whether treatment with amiloride prevents the arterial stiffness caused by a high-salt diet. Study design: Randomized, double blinded and placebo-controlled clinical trial with open-label treatment with amiloride Study population: Adults with ADPKD with an estimated glomerular filtration rate (CKD-EPI) of ≥ 60 ml/min/1.73m2 Intervention: All participants will be subjected to a low-salt diet (3,5 grams/day) throughout the study for a total of 6 weeks. After a run-in period of 2 weeks, participants will be randomized into two treatment groups: Group 1: Sodium chloride capsules (6 grams/day) for 2 weeks, combined with amiloride (20 mg/day) in last 2 weeks Group 2: Placebo capsules for 2 weeks, combined with amiloride (20 mg/day) in last 2 weeks. Primary study parameters/outcome of the study: The three primary outcomes of this study are a difference in central arterial stiffness (pulse wave velocity, PWV) between: 1. The high-salt group versus low-salt group; 2. The high-salt group: before versus after amiloride treatment; 3. The low-salt group: before versus after amiloride treatment. The burden of participation includes: - A dietary salt restriction of 3.5 grams/day for a total period of 6 weeks - Salt supplementation or placebo for a total period of 4 weeks - Drug intervention with amiloride during the last 2 weeks - Hospital visits ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04310319 -
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
|
N/A | |
Recruiting |
NCT03596957 -
Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 4 | |
Terminated |
NCT04064346 -
Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
Completed |
NCT03203642 -
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
|
Phase 2 | |
Recruiting |
NCT05500157 -
Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts
|
N/A | |
Recruiting |
NCT04111692 -
A Prospective Observational Study of Foam Sclerotherapy .
|
||
Recruiting |
NCT04907799 -
Daily Caloric Restriction in ADPKD
|
N/A | |
Completed |
NCT05401409 -
Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Terminated |
NCT03918447 -
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
|
Phase 3 | |
Terminated |
NCT03749447 -
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
|
Phase 3 | |
Completed |
NCT04908462 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03858439 -
Dietary Intervention in ADPKD on Tolvaptan
|
N/A | |
Recruiting |
NCT06391450 -
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
|
Phase 4 | |
Recruiting |
NCT05478083 -
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
|
Phase 2 | |
Completed |
NCT03102632 -
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Recruiting |
NCT05996731 -
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
|
N/A | |
Recruiting |
NCT06193616 -
Outcome of ADPKD With Octreotide LAR
|
||
Completed |
NCT05646420 -
Thyroid Hormones in ADPKD
|
N/A | |
Completed |
NCT03366337 -
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
|
Phase 2 | |
Active, not recruiting |
NCT03273413 -
Statin Therapy in Patients With Early Stage ADPKD
|
Phase 4 |